Your browser doesn't support javascript.
loading
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu, Hongxi; Zhang, Lulu; Gao, Xiaofang; Zhang, Xiuna; Duan, Jingjing; You, Linjun; Cheng, Yan; Bian, Jinsong; Zhu, Qingyi; Yang, Yong.
Afiliación
  • Wu H; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • Zhang L; Department of Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, China.
  • Gao X; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • Zhang X; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • Duan J; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • You L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • Cheng Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China.
  • Bian J; Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore.
  • Zhu Q; Department of Urology, Jiangsu Province Hospital of TCM, Nanjing 210029, China. Electronic address: zhuqy1971@126.com.
  • Yang Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, Center for New Drug Safety Evaluation and Research, China Pharmaceutical University, Nanjing 211198, China. Electronic address: yy@cpu.edu.cn.
Cancer Lett ; 385: 108-116, 2017 01 28.
Article en En | MEDLINE | ID: mdl-27815035
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Feniltiohidantoína / Compuestos de Fenilurea / Protocolos de Quimioterapia Combinada Antineoplásica / Niacinamida / Inhibidores de Proteínas Quinasas / Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Lett Año: 2017 Tipo del documento: Article País de afiliación: China
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Feniltiohidantoína / Compuestos de Fenilurea / Protocolos de Quimioterapia Combinada Antineoplásica / Niacinamida / Inhibidores de Proteínas Quinasas / Neoplasias de la Próstata Resistentes a la Castración / Antagonistas de Andrógenos Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Lett Año: 2017 Tipo del documento: Article País de afiliación: China